Survival After Prior CDK4/6 Inhibition and Delaying Chemotherapy

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, presents exploratory overall survival data from CAPItello-291 in patients with prior cyclin-dependent kinase (CDK) 4/6 inhibitor exposure, showing about a 7-month difference favoring capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered population of this hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer trial, without statistical significance. Sarah L. Sammons, MD, of the University of Maryland Greenebaum Comprehensive Cancer Center, resists calling it a trend but will continue using the regimen in altered disease, noting the absence of a survival benefit leaves room for future novel agents. The faculty then review progression-free survival 2, improved from 11 to about 16 months (hazard ratio, 0.68) in the altered population, and time to first subsequent chemotherapy, extended from 6 to 11 months. Dr Sammons and Dr Mayer both prize delaying chemotherapy as a tangible, patient-comprehensible measure of benefit.